Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Duminuco

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Frontiers in Oncology|April 17, 2023
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimabAndrea Duminuco, Alessandra Romano, Dario Leotta, et al.
Journal of Clinical Medicine|July 29, 2025
Real-World Outcomes in <i>FLT3</i>-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric CohortVeronica Vecchio, Andrea Duminuco, Salvatore Leotta, et al.
Vaccines|February 26, 2025
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center ExperienceAndrea Duminuco, Anna Bulla, Rosamaria Rosso, et al.
Annals of Hematology|April 17, 2024
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life surveyAndrea Duminuco, Alessandra Romano, Isacco Ferrarini, et al.
Journal of Clinical Medicine|January 8, 2025
Emergencies in Hematology: Why, When and How I Treat?Andrea Duminuco, Vittorio Del Fabro, Paola De Luca, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic LandscapeAndrea Duminuco, Patrick Harrington, Vittorio Del Fabro, et al.
Cancers|August 26, 2023
Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life StudyVittorio Del Fabro, Mary Ann Di Giorgio, Valerio Leotta, et al.
Journal of Clinical Medicine|March 25, 2022
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic SyndromesCalogero Vetro, Valeria Di Giacomo, Donato Mannina, et al.
Frontiers in Immunology|October 9, 2023
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experienceAndrea Duminuco, Uros Markovic, Nunziatina Laura Parrinello, et al.
European Journal of Haematology|November 24, 2025
Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life StudyAndrea Duminuco, Vittorio Del Fabro, Gabriella Santuccio, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Frontiers in Oncology|April 17, 2023
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimabAndrea Duminuco, Alessandra Romano, Dario Leotta, et al.
Journal of Clinical Medicine|July 29, 2025
Real-World Outcomes in <i>FLT3</i>-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric CohortVeronica Vecchio, Andrea Duminuco, Salvatore Leotta, et al.
Vaccines|February 26, 2025
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center ExperienceAndrea Duminuco, Anna Bulla, Rosamaria Rosso, et al.
Annals of Hematology|April 17, 2024
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life surveyAndrea Duminuco, Alessandra Romano, Isacco Ferrarini, et al.
Journal of Clinical Medicine|January 8, 2025
Emergencies in Hematology: Why, When and How I Treat?Andrea Duminuco, Vittorio Del Fabro, Paola De Luca, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic LandscapeAndrea Duminuco, Patrick Harrington, Vittorio Del Fabro, et al.
Cancers|August 26, 2023
Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life StudyVittorio Del Fabro, Mary Ann Di Giorgio, Valerio Leotta, et al.
Journal of Clinical Medicine|March 25, 2022
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic SyndromesCalogero Vetro, Valeria Di Giacomo, Donato Mannina, et al.
Frontiers in Immunology|October 9, 2023
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experienceAndrea Duminuco, Uros Markovic, Nunziatina Laura Parrinello, et al.
European Journal of Haematology|November 24, 2025
Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life StudyAndrea Duminuco, Vittorio Del Fabro, Gabriella Santuccio, et al.
Pageof 8